Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KSD-101 Therapy for EBV-associated Haematologic Neoplasms
NCT05635591Phase 1Enrolling by invitation
- Sponsor
- Tongji Hospital
- Start
- Jan 2023
- Primary completion
- Dec 2026
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous monocyte-derived DCs pulsed with EBV antigen in Epstein-Barr virus-associated hematologic neoplasms (EBV-LPD), sponsored by Tongji Hospital. Primary endpoints: Dose-Limiting Toxicity at 1 year, Maximum Tolerated Dose at 1 year and 1 more. Started Jan 2023; status: enrolling by invitation.
02
Drugs
autologous monocyte-derived DCs pulsed with EBV antigen
03
Conditions
Epstein-Barr virus-associated hematologic neoplasms (EBV-LPD)
Beyond the preview
Go deeper on NCT05635591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05635591.